Developing a vaccine to combat Hepatitis C virus
Official title: Precision Glycoengineering of an HCV Envelope-Based Nanoparticle Vaccine
Funded at Neuimmune Biologics, INC. · NIH-10759994 · Data updated 2026-11-12
This study is working on a new vaccine for Hepatitis C that uses a special part of the virus to help your body build a strong defense against it, which could lead to a more effective and reliable way to protect people from the virus.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Neuimmune Biologics, INC. NIH-funded |
| Lab location | 1 site (Sykesville, United States) |
| Project start | July 17, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $300,000 |
| NIH project number | 1R41AI179330-01 |
| Project ID | NIH-10759994 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk of Hepatitis C virus infection or those who are currently infected.
✕Less likely to help
Patients who are not at risk for Hepatitis C or those who have already been effectively treated and cleared of the virus may not benefit from this research.
What this research studies
This research focuses on creating a vaccine for Hepatitis C virus (HCV) by engineering a specific viral protein to elicit a strong immune response. The approach involves producing a stable and effective form of the viral envelope protein E1E2 in specially modified mammalian cell lines. By ensuring that the vaccine can consistently produce broadly neutralizing antibodies, the research aims to overcome challenges related to variations in vaccine production. Patients may benefit from a more effective and reliable vaccine against HCV if successful.
Why it matters
Potential benefit: If successful, this research could lead to a highly effective vaccine that protects against Hepatitis C virus infections.
How similar studies have gone: Other research has shown promise in developing vaccines targeting viral infections using similar glycoengineering approaches, indicating potential for success in this area.
Where this research is happening
-
Neuimmune Biologics, INC.
Sykesville, United States Active
Researchers
- Principal investigator: Horrigan, Stephen Kevin — Neuimmune Biologics, INC.
- Study coordinator: Horrigan, Stephen Kevin
Related research
Other NIH-funded projects on the same topics.
-
Consultation services for biological therapeutics development
This study is all about helping scientists create better biological treatments for different health conditions by providing expert advice, which could ultimately lead to more effective therapies for patients like you.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.